Johnson & Johnson (JNJ) — insider trading
Health Care · NYSE
Johnson & Johnson (JNJ) has 47 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 47 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Pinto Daniel E | Director | Grant / award / vesting (derivative) | 113 | $276.31 | $31.3K | Form 4 |
| 2026-09-08 | Woods Eugene A. | Director | Grant / award / vesting (derivative) | 136 | $276.31 | $37.5K | Form 4 |
| 2026-09-08 | HEWSON MARILLYN A | Director | Grant / award / vesting (derivative) | 181 | $276.31 | $50.0K | Form 4 |
| 2026-09-02 | Schmid Timothy | Officer (EVP, WW Chair, MedTech) | Option exercise / conversion (derivative) | 22,527 | — | $0 | Form 4 |
| 2026-09-02 | Schmid Timothy | Officer (EVP, WW Chair, MedTech) | Option exercise / conversion (derivative) | 11,070 | — | $0 | Form 4 |
| 2026-09-02 | Schmid Timothy | Officer (EVP, WW Chair, MedTech) | Open-market sale | 22,527 | $274.74 | $6.19M | Form 4 |
| 2026-09-02 | Schmid Timothy | Officer (EVP, WW Chair, MedTech) | Option exercise / conversion | 22,527 | $151.41 | $3.41M | Form 4 |
| 2026-09-02 | Schmid Timothy | Officer (EVP, WW Chair, MedTech) | Open-market sale | 11,070 | $274.74 | $3.04M | Form 4 |
| 2026-09-02 | Schmid Timothy | Officer (EVP, WW Chair, MedTech) | Option exercise / conversion | 11,070 | $131.94 | $1.46M | Form 4 |
| 2026-08-17 | Taubert Jennifer L | Officer (EVP, WWC. Innovative Medicine) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-08-17 | Taubert Jennifer L | Officer (EVP, WWC. Innovative Medicine) | Open-market sale | 15,000 | $263.36 | $3.95M | Form 4 |
| 2026-08-17 | Taubert Jennifer L | Officer (EVP, WWC. Innovative Medicine) | Option exercise / conversion | 15,000 | $115.67 | $1.74M | Form 4 |
| 2026-08-13 | Duato Joaquin | Director, Officer (CEO and Chairman of the Board) | Option exercise / conversion (derivative) | 123,291 | — | $0 | Form 4 |
| 2026-08-13 | Duato Joaquin | Director, Officer (CEO and Chairman of the Board) | Open-market sale | 102,315 | $261.00 | $26.70M | Form 4 |
| 2026-08-13 | Duato Joaquin | Director, Officer (CEO and Chairman of the Board) | Open-market sale | 20,976 | $262.00 | $5.50M | Form 4 |
| 2026-08-13 | Duato Joaquin | Director, Officer (CEO and Chairman of the Board) | Option exercise / conversion | 123,291 | $115.67 | $14.26M | Form 4 |
| 2026-08-06 | Forminard Elizabeth | Officer (EVP, Chief Legal Officer) | Option exercise / conversion (derivative) | 9,344 | — | $0 | Form 4 |
| 2026-08-06 | Forminard Elizabeth | Officer (EVP, Chief Legal Officer) | Open-market sale | 6,574 | $255.93 | $1.68M | Form 4 |
| 2026-08-06 | Forminard Elizabeth | Officer (EVP, Chief Legal Officer) | Open-market sale | 9,344 | $257.76 | $2.41M | Form 4 |
| 2026-08-06 | Forminard Elizabeth | Officer (EVP, Chief Legal Officer) | Option exercise / conversion | 9,344 | $131.94 | $1.23M | Form 4 |
| 2026-08-05 | Duato Joaquin | Director, Officer (CEO and Chairman of the Board) | Open-market sale | 6,523 | $258.74 | $1.69M | Form 4 |
| 2026-08-05 | Duato Joaquin | Director, Officer (CEO and Chairman of the Board) | Open-market sale | 41,957 | $258.06 | $10.83M | Form 4 |
| 2026-07-20 | Broadhurst Vanessa | Officer (EVP, Global Corp Affairs) | Option exercise / conversion (derivative) | 11,925 | — | $0 | Form 4 |
| 2026-07-20 | Broadhurst Vanessa | Officer (EVP, Global Corp Affairs) | Option exercise / conversion (derivative) | 11,129 | — | $0 | Form 4 |
| 2026-07-20 | Broadhurst Vanessa | Officer (EVP, Global Corp Affairs) | Open-market sale | 23,054 | $251.27 | $5.79M | Form 4 |
| 2026-07-20 | Broadhurst Vanessa | Officer (EVP, Global Corp Affairs) | Option exercise / conversion | 11,925 | $131.94 | $1.57M | Form 4 |
| 2026-07-20 | Broadhurst Vanessa | Officer (EVP, Global Corp Affairs) | Option exercise / conversion | 11,129 | $129.51 | $1.44M | Form 4 |
| 2026-06-11 | Wengel Kathryn E | Officer (EVP, Chief TO and Risk Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-11 | Wengel Kathryn E | Officer (EVP, Chief TO and Risk Officer) | Open-market sale | 10,000 | $241.15 | $2.41M | Form 4 |
| 2026-06-11 | Wengel Kathryn E | Officer (EVP, Chief TO and Risk Officer) | Option exercise / conversion | 10,000 | $115.67 | $1.16M | Form 4 |
| 2026-06-09 | HEWSON MARILLYN A | Director | Grant / award / vesting (derivative) | 215 | $232.79 | $50.0K | Form 4 |
| 2026-06-09 | Pinto Daniel E | Director | Grant / award / vesting (derivative) | 134 | $232.79 | $31.2K | Form 4 |
| 2026-06-09 | Woods Eugene A. | Director | Grant / award / vesting (derivative) | 161 | $232.79 | $37.5K | Form 4 |
| 2026-05-01 | REED JOHN C | Officer (EVP, Innovative Medicine, R&D) | Option exercise / conversion (derivative) | 25,255 | — | $0 | Form 4 |
| 2026-05-01 | REED JOHN C | Officer (EVP, Innovative Medicine, R&D) | Shares withheld for taxes / exercise cost | 11,002 | $229.85 | $2.53M | Form 4 |
| 2026-05-01 | REED JOHN C | Officer (EVP, Innovative Medicine, R&D) | Option exercise / conversion | 25,255 | — | $0 | Form 4 |
| 2026-04-23 | Beckerle Mary C | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | Doudna Jennifer A | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | HEWSON MARILLYN A | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | Johnson Paula A | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | Joly Hubert | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | McClellan Mark B. | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | MORIKIS JOHN G | Director | Grant / award / vesting (derivative) | 1,540 | — | $0 | Form 4 |
| 2026-04-23 | Pinto Daniel E | Director | Grant / award / vesting (derivative) | 1,712 | — | $0 | Form 4 |
| 2026-04-23 | WEINBERGER MARK A | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | West Nadja | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
| 2026-04-23 | Woods Eugene A. | Director | Grant / award / vesting (derivative) | 975 | — | $0 | Form 4 |
Ask the chat about JNJ's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Johnson & Johnson (JNJ).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.